Sustained Remission Off‐Therapy in a Case of Infantile ALK‐Positive Multisystem Histiocytosis Treated With Crizotinib

This publication has 14 references indexed in Scilit:

• Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial
  European Journal of Cancer, 2023
• Lorlatinib use in an infant with thalamic ALK‐positive histiocytosis
  Pediatric Blood & Cancer, 2023
• Histiocytosis
  The Lancet, 2021
• Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms
  Nature Medicine, 2019
• ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion
  Laboratory Investigation, 2019
• Dosing anticancer drugs in infants: Current approach and recommendations from the Children's Oncology Group's Chemotherapy Standardization Task Force
  Pediatric Blood & Cancer, 2017
• Crizotinib resistance: implications for therapeutic strategies
  Annals of Oncology, 2016
• Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
  Blood, 2016
• Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
  The Lancet Oncology, 2013
• ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy
  Blood, 2008